Drug Trial Radar · NCT04551066
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
252
Actual
Start
May 24, 2021
Primary completion
Aug 3, 2023
Study completion Nov 25, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Conditions
- Myelofibrosis
- Primary Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
Interventions
parsaclisibDrug
parsaclisib will be administered QD orally
ruxolitinibDrug
ruxolitinib will be administered BID orally
placeboDrug
placebo will be administered QD orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 as Measured by Magnetic Resonance Imaging [MRI] (or Computed Tomography [CT] Scan in Applicable Participants)Time frame: Baseline; Week 24
Locations
177 sites in 17 countries. Site status is shown where the registry gives one.
Alaska Oncology and Hematology
Anchorage, Alaska
Mayo Clinic Rochester
Phoenix, Arizona
Sutter Health Alta Bates Summit Medical Center Absmc Alta Bates Summit Comprehensive Cancer Center
Berkeley, California
CCARE
Fresno, California
California Research Institute (Cri)
Los Angeles, California
UCLA School of Medicine
Los Angeles, California
Scripps Clinic
San Diego, California
Coastal Integrated Cancer Care-Cicc
San Luis Obispo, California
Stamford Hospital-Medical Oncology Hematology
Stamford, Connecticut
Georgetown University
Washington D.C., District of Columbia
Emory University
Atlanta, Georgia
University of Kansas Hospital Authority
Westwood, Kansas
University of Kentucky-Markey Cancer Center
Lexington, Kentucky
Tulane University
New Orleans, Louisiana
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Midamerica Cancer Care
Kansas City, Missouri
New Jersey Hematology Oncology Associates Llc
Brick, New Jersey
Morristown Medical Center-Atlantic Health System
Morristown, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Westchester Medical Center Advanced Oncology and Infusion Center
Hawthorne, New York
Mount Sinai School of Medicine
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Duke Cancer Center
Durham, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Ohio State University
Columbus, Ohio
Kaiser Permanente-Northwest
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Avera Cancer Institute
Sioux Falls, South Dakota
Texas Oncology-Baylor Sammons Cancer Center
Dallas, Texas
Kelsey Seybold Clinic
Houston, Texas
Houston Methodist Hospital
Houston, Texas
Renovatio Clinical
Spring, Texas
Providence Regional Medical Center Everett
Everett, Washington
Seattle Cancer Care Alliance
Seattle, Washington
Ordensklinikum Linz Gmbh Elisabethinen
Linz, Austria
Universitaetsklinikum St. Poelten
Saint P�LTEN, Austria
Hanusch-Krankenhaus Der Wiener Gebietskrankenkasse
Vienna, Austria
Hanusch-Krankenhaus Wiener Gebietskrankenkasse
Vienna, Austria
Showing 40 of 177 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.